SUMMARY Ciprofloxacin, a quinolone antibacterial, was evaluated in the treatment of gonococcal, chlamydial, gonococcal and chlamydial, and non-gonococcal non-chlamydial urethritis. The dosage regimen used was 500 mg orally twice a day for seven days. Of the 56 patients evaulated, 22 had gonococcal infection only, 13 were infected with Chlamydia trachomatis only, seven had combined infection, and 14 were harbouring neither of these organisms. Neisseria gonorrhoeae was cleared in all the 29 patients with or without chlamydial infection. Of those who denied having sexual intercourse during the follow up period, post gonococcal urethritis (PGU) developed in 12 (63%) out of 19, C trachomatis was isolated again from 11 (78%) out of 14, and urethritis recurred in five (55%) out of nine patients with non-gonococcal non-chlamydial infection. There was also evidence that the dosage regimen used was only partially effective against Ureaplasma urealyticum.
Introduction
Urethritis is the commonest manifestation of sexually transmitted disease (STD) in England. In 1983 97 673 new cases of non-gonococcal urethritis (NGU) and 30 464 cases of gonorrhoea were diagnosed in men in clinics in England.' Reports from some countries showed that in about 60% of men with NGU Chlamydia trachomatis was the sole causative organism,2 but in 23% to 40% of men with gonorrhoea and about 50% of women with gonorrhoea, C trachomatis was also present as a concurrent infection.3 6 The widely practised treatment of gonorrhoea with penicillin or alternative agents (such as spectinomycin), which have no effect on C trachomatis, is therefore increasingly thought to be undesirable as patients presenting with both infections concurrently will probably have persistent chlamydial infection after the gonorrhoea has been cured.
Such persistent chlamydial infection may be completely silent or may give signs or symptoms of postgonococcal urethritis in men, with a possibility of later epididymitis, or of postgonococcal cervicitis in women, with a risk of spread to sexual partners or neonates and of pelvic inflammatory disease or perihepatitis. For example, up to 50% of men with gonorrhoea develop PGU, which is asymptomatic in about half the patients.6 In 80% of patients with asymptomatic PGU the cause was unresolved chlamydial infection, which had been present concurrently with gonorrhoea before treatment. 7 Similarly, over 60% of women with combined gonococcal and chlamydial infection had persistent cervicitis after treatment with penicillin because the drug had failed to cure the chlamydial infection. 6 8 None of the more recent B lactam antibiotics is more effective than penicillin against chlamydiae. (table II) . In none ofthese were chlamydiae isolated at the first follow up, in five C trachomatis was isolated again at the second follow up visit (one week after the completion of treatment), and in a further six at the third follow up visit (two weeks after the completion of treatment). Of the three patients from whom Ctrachomatis was not isolated again, one had to be treated again at the first follow up visit because of persistent overt urethral discharge, another was treated again at the end of three weeks because of persistent urethritis, though his chlamydia swab was negative, and the third remained free of symptoms and signs for up to six weeks, after which he defaulted.
Only four ofthe 11 patients were symptomatic at the time that C trachomatis was isolated again after treatment. In eight the signs of urethritis were minimal -scanty clear discharge demonstrable only on massaging the urethra. Microscopy showed 5 or more PMNL/hpf in all 11 patients. Most had held urine for over four hours. Urethritis persisted or relapsed in 10 of the 13 patients originally infected with C trachomatis only.
Non-gonococcal non-chiamydial urethritis Of the 14 patients evaluated, 10 needed treatment again for persistence or recurrence of urethritis seven within two weeks after the completion of treatment. Two patients treated again six weeks after the initial treatment were thought to have been reinfected. Though all patients were initially symptomatic, only five had symptoms when they were treated again.
Side effects
None of the patients volunteered that they had experienced any untoward effects. When they were questioned, eight had experienced possible side effects, which were all mild; they included tiredness, sleepiness, insomnia, headache, dizziness, erythema, abdominal discomfort, chest pain, and dry throat. The total serum bilirubin concentration was found to be slightly raised in one patient from 14 s molA before treatment to 22 >t mol/l after treatment (normal 2 to 17 p molA). It had reverted to normal when the test was repeated a week later.
Mycoplasmas
Of the nine patients from whom Uurealyticum had been isolated before treatment, seven gave a negative result one week after treatment, with only one patient still culture positive. Two weeks after treatment, three patients had become positive for Uurealyticum and four still remained negative. Mhominis was not isolated again after ciprofloxacin treatment, and the three patients initially yielding it remained negative throughout the follow up period.
Discussion
It is always difficult to distinguish relapse from reinfection when evaluating the outcome of treatment of an STD. The bias resulting from possibly inaccurate sexual histories can be minimised by cross checking with the case sheets of sexual partners and taking into account the details of sexual history obtained at each visit, as attempted in this study (table II) .
Recurrence of chlamydial infections may not be detectable by tissue culture methods until several weeks after treatment, either because of spontaneous periodical variations in the amount of chlamydial growth or because partial antibiotic suppression has reduced the degree and rate of maturation of chlamydiae in persistent foci. This particularly occurs with B lactam agents.9 Thus the difficulty in distinguishing relapse from reinfection is even greater than with gonorrhoea, as the patients may well have resumed sexual intercourse in the long follow up period needed.
The optimum follow up period to confirm cure or detect failure for a particular drug regimen in treating chlamydial infection is unknown, but obviously depends on the dose and duration of treatment as well as other factors. In this study, using ciprofloxacin 500mg twice a day for one week, Ctrachomatis was not isolated again at the first follow-up visit in any of the 14 originally infected patients who denied having had sexual intercourse, and a further two weeks' follow up was necessary to detect all treatment failures.
The minimal signs and absence of symptoms in over half our patients from whom C trachomatis was isolated again were consistent with some degree of clinical recovery, possibly due to the partial suppression of C trachomatis by ciprofloxacin. The difference between the MIC and the minimum bactericidal concentration (MBC) There was no opportunity in the present study to compare the efficacy of ciprofloxacin with that of other chemotherapeutic regimens. Nevertheless, the degree of failure of ciprofloxacin to cure chlamydial infection is clearly beyond the normal expectation of routine tetracycline treatment in this and other clinics. Moreover, in a similar study (Arya and Mallinson, unpublished data) of patients seen by the same clinician (OPA) as in the present trial, men with chlamydial urethritis treated with either oxytetracycline 250 mg four times a day for seven days or sustained release tetracycline hydrochloride 500 mg initially followed by 250 mg twice a day for seven days showed, in patients who had not had sexual intercourse, a failure rate of only 14% (two out of 14 treated with oxytetracycline and three out of 22 treated with tetracycline hydrochloride) compared with 78% (11 out of 14 patients) treated with ciprofloxacin in the present study. The difference between the ciprofloxacin regimen and either of. the tetracycline regimens was significant (p<0-01). Treatment with oxytetracycline for 14 days resulted in cure in all 15 patients (Arya and Mallinson, unpublished data).
Treatment with ciprofloxacin seemed to be successful in eradicating Mhominis from the urethras of men, but the same cannot be said for its effect on Uurealyticum. Seven out of the original nine positive patients were still being followed up two weeks after treatment, and Uurealyticum was isolated again from three of them. This suggested that, though it seemed to be initially effective, ciprofloxacin was not able to eradicate the organism, which was able to re-establish itself.
We conclude that ciprofloxacin 500 mg twice a day for seven days cures gonorrhoea but is unsatisfactory for aborting postgonoccoccal urethritis and for treating non-specific urethritis, is only partially effective against Uurealyticum, and is almost completely ineffective against C trachomatis. Because of the last observation it was considered unethical to proceed with the clinical trial with the dosage regimen used, and the trial was therefore abandoned.
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